title: Comparing effects of citalopram with fluoxetine on sleep quality in patients with major depressive disorder.
abstract: BACKGROUND
  Sleep disturbance is a common complaint in major depressive disorder (MDD) including impairment of both subjective and objective parameters. All antidepressants affect sleep architecture and quality.
  
  
  OBJECTIVE
  This trial was designed to compare the effects of short-term use of citalopram with fluoxetine on sleep quality (SQ) of patients with MDD based on Diagnostic and Statistical Manual for Mental Disorders - Text Revision 4th edition (DSM-IV-TR) criteria.
  
  
  METHODS
  Patients who met the study criteria entered this open-label study. Sleep quality and depression severity were evaluated by using Pittsburgh Sleep Quality Index (PSQI) and Beck Depression Inventory-II (BDI-II), respectively. Patients could not have received any antidepressant for at least one month prior entering the study. Subjects were assigned to receive either fluoxetine or citalopram for 8 weeks. The relationships between SQ and severity of depression were also studied at weeks 4 and 8. Data was analyzed by using SPSS 11.5 version.
  
  
  RESULTS
  Nineteen patients received fluoxetine 20-40 mg/day and 21 received citalopram 20-40 mg/day. After 4 and 8 weeks treatment with both fluoxetine and citalopram, significant improvements in SQ were noted in both groups. However, no significant difference between the two groups was observed. Additionally, a significant and positive correlation between improvements in SQ and depression was noted after 8 weeks treatment with citalopram but not with fluoxetine.
  
  
  CONCLUSIONS
  This study noted that both citalopram and fluoxetine improved SQ in outpatients with MDD after 8 weeks without any significant difference between the 2 groups.
authors.affiliation: Department of Genomic Psychiatry, Tehran University of Medical Sciences, Tehran, Iran.
authors.forename: E
authors.initials: E
authors.lastname: Shahsavand-Ananloo
authors.forename: F
authors.initials: F
authors.lastname: Berenji
authors.forename: K
authors.initials: K
authors.lastname: Sadeghniiat
authors.forename: A
authors.initials: A
authors.lastname: Alimadadi
authors.forename: A R
authors.initials: AR
authors.lastname: Zahiroddin
authors.forename: M
authors.initials: M
authors.lastname: Tabatabaee
authors.forename: M
authors.initials: M
authors.lastname: Abbasi-Asl
authors.forename: P
authors.initials: P
authors.lastname: Ghaeli
mesh_terms: D000293:Adolescent; D000328:Adult; D015283:Citalopram / Q000627:therapeutic use*; D003865:Major Depressive Disorder / Q000150:complications* / Q000188:drug therapy* / Q000523:psychology; D039721:Diagnostic and Statistical Manual of Mental Disorders; D005260:Female; D005473:Fluoxetine / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011569:Psychiatric Status Rating Scales; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use*; D012890:Sleep / Q000187:drug effects*; D012893:Sleep Wake Disorders / Q000188:drug therapy* / Q000209:etiology*; D055815:Young Adult
chemical_list: D015283:Citalopram; D005473:Fluoxetine; D017367:Selective Serotonin Reuptake Inhibitors